What was the average weight loss in the ATTAIN trial?

The average weight loss was 30.4 pounds among participants.

When will Eli Lilly's oral weight-loss drug be available?

Eli Lilly has not announced a commercial launch date yet, but may file for FDA approval soon.

How does this drug compete with other obesity drugs like Wegovy?

The drug targets a demographic with hormonal challenges, potentially giving it a competitive edge, especially for menopausal women.

Eli Lilly's Weight-Loss Pill Clears Its Toughest Hormonal Test Yet

Eli Lilly announced positive results from its ATTAIN clinical trial for an oral weight-loss drug, showing up to 30.4 pounds of weight loss in perimenopausal and post-menopausal women.

June 8, 2026

2 min read

Source: GuruFocus.com

Key Numbers

weight loss

30.4 lbs

Eli Lilly (NYSE: LLY) announced positive results from its ATTAIN clinical trial for an oral weight-loss drug, demonstrating up to 30.4 pounds of weight loss in perimenopausal and post-menopausal women.

The Product

The oral drug, yet to be named, is part of Eli Lilly's obesity treatment pipeline. The trial focused on a demographic facing hormonal challenges that affect weight loss, potentially giving the drug a competitive edge.

Pricing and Availability

Eli Lilly has not disclosed pricing or a commercial launch timeline. The company is expected to file for FDA approval in the near future.

Competition

Eli Lilly faces stiff competition in the obesity drug market, particularly from Novo Nordisk (NYSE: NVO) with its Wegovy drug. However, ATTAIN results may give Lilly an advantage in targeting women during sensitive hormonal stages.

Potential Impact on the Company

If approved, the drug could significantly boost Eli Lilly's revenue in the growing obesity sector. The obesity drug market is estimated to be worth tens of billions of dollars, and this underserved demographic could represent a major opportunity.

Frequently Asked Questions

The ATTAIN trial is a clinical study of an oral weight-loss drug from Eli Lilly, focusing on perimenopausal and post-menopausal women.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.